Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.02 SEK | 0.00% |
|
-2.58% | +12.27% |
24/06 | CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01 | CI |
27/05 | CombiGene Appoints New Chief Scientific Officer | MT |
Business Summary
Number of employees: 10
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Gene Therapies
100.0
%
| 27 | 100.0 % | 6 | 100.0 % | -79.23% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 27 | 100.0 % | 6 | 100.0 % | -79.23% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Ekolind
CEO | Chief Executive Officer | 60 | 27/22/27 |
Louise Aspenberg
DFI | Director of Finance/CFO | 48 | 12/20/12 |
Daniela Morath
ADM | Chief Administrative Officer | 44 | 01/18/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gunilla Lundmark
BRD | Director/Board Member | 61 | 01/21/01 |
Chairman | 59 | 01/20/01 | |
Director/Board Member | 54 | 01/14/01 | |
Per Lundin
BRD | Director/Board Member | 41 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 19,801,197 | 11,880,966 ( 60.00 %) | 0 | 60.00 % |
Company contact information
![address CombiGene AB(COMBI)](https://cdn.zonebourse.com/static/address/49649104.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+12.27% | 5.66M | |
+16.49% | 122B | |
+21.73% | 115B | |
+22.30% | 26.64B | |
-21.81% | 19.91B | |
-16.66% | 16.32B | |
-18.81% | 15.49B | |
-44.74% | 15.52B | |
+62.72% | 14.83B | |
+3.09% | 13.67B |
- Stock Market
- Equities
- COMBI Stock
- Company CombiGene AB